Cantargia announces publication of two scientific articles on nadunolimab
Cantargia AB today reported publication of two articles in peer-reviewed scientific journals. The first, published in British Journal of Cancer, presents results from the phase 1 part of the CANFOUR clinical trial where the safety of nadunolimab was evaluated. The second, published in Frontiers in Immunology, presents findings related to functional, biophysical and structural analyses of the interactions between nadunolimab and its target IL1RAP.Cantargia today reported publication of two articles in peer-reviewed scientific journals. The first article, published in British Journal of